The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
The global market for AI in life sciences software is estimated to grow from $6.5 billion in 2024 to $24.7 billion by the end of 2029, at a CAGR of 30.4% from 2024 to 2029.
The global market for AI in life sciences services is estimated to grow from $3.2 billion in 2024 to $8.8 billion by the end of 2029, at a CAGR of 22.1% from 2024 to 2029.
Report Scope:
This report aims to comprehensively study the market size of global artificial intelligence (AI) in the life sciences. Current and historical market revenues can be estimated based on products, applications, end users, and regions.
Report Includes:
- 26 data tables and 35 additional tables
- Analyses of trends in the global market for AI in life sciences, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the current market size and revenue prospects, along with a market share analysis based on product segment, application, end user and region
- Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario and the expected impact of macroeconomic factors
- Identification of the AI products and technologies with the highest commercial potential, and their relevant applications in life sciences, specifically precision medicine and personalized healthcare
- Overview of ESG developments and sustainability trends, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
- Review of patent activity and key patent grants
- An analysis of the industry structure, including companies' market shares, merger and acquisition activity, and venture funding outlook
- Profiles of the leading companies, including AiCure LLC., Apixio Inc., Atomwise Inc., BenevolentAI and NuMedii Inc.